GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EV-to-EBITDA

Vectus Biosystems (ASX:VBS) EV-to-EBITDA : -0.56 (As of Jul. 10, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vectus Biosystems's enterprise value is A$1.25 Mil. Vectus Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.21 Mil. Therefore, Vectus Biosystems's EV-to-EBITDA for today is -0.56.

The historical rank and industry rank for Vectus Biosystems's EV-to-EBITDA or its related term are showing as below:

ASX:VBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.56   Med: 0   Max: 0
Current: -0.56

ASX:VBS's EV-to-EBITDA is ranked worse than
100% of 469 companies
in the Biotechnology industry
Industry Median: 10.09 vs ASX:VBS: -0.56

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-10), Vectus Biosystems's stock price is A$0.038. Vectus Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.043. Therefore, Vectus Biosystems's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Vectus Biosystems EV-to-EBITDA Historical Data

The historical data trend for Vectus Biosystems's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems EV-to-EBITDA Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -8.14 -12.04 -12.33 -6.42 -1.46

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.42 - -1.46 -

Competitive Comparison of Vectus Biosystems's EV-to-EBITDA

For the Biotechnology subindustry, Vectus Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's EV-to-EBITDA falls into.


;
;

Vectus Biosystems EV-to-EBITDA Calculation

Vectus Biosystems's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1.245/-2.209
=-0.56

Vectus Biosystems's current Enterprise Value is A$1.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-2.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Vectus Biosystems's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.038/-0.043
=At Loss

Vectus Biosystems's share price for today is A$0.038.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.043.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Vectus Biosystems EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines